Active ingredientFosravuconazole Disodium SaltCat. No. P-F123-001CAS 351227-62-8Family · Pharmaceutical analytical standards
Fosravuconazole
An oral triazole antifungal, a prodrug the body converts into ravuconazole: it was approved in Japan in 2018 to treat onychomycosis, the fungal infection of the nails. This family brings together the active ingredient and other impurities.
Did you know?From nail drug to hope for a neglected disease: in a phase II trial run with the non-profit DNDi it proved effective against eumycetoma, which mainly affects young adults in poor rural areas.
Go to the active ingredient →Active ingredientFosravuconazole Disodium SaltCat. No. P-F123-001CAS 351227-62-8
ImpurityFosravuconazole Amide ImpurityCat. No. P-F123-002CAS 942415-34-1
ImpurityFosravuconazole Impurity 1Cat. No. P-F123-003
ImpurityFosravuconazole Impurity 2Cat. No. P-F123-004
ImpurityFosravuconazole L-Lysine EthanolateCat. No. P-F123-005CAS 914361-45-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.